From the PharmaLive.com News Archive - Jun. 17, 2008 LAS VEGAS--(BUSINESS WIRE)--Jun 17, 2008 - Samaritan Pharmaceuticals (OTCBB:SPHC) (http://www.samaritanpharma.com), a biopharmaceutical company committed to commercializing new and innovative therapeutic drugs, announced today that it has received pricing approval for Rapydan(R) from the Greek Ministry of Development and is launching the novel rapid-onset anesthetic patch in Greece this week. Rapydan(R), a medicated plaster, is manufactured by EUSA Pharma. The easy-to-use plaster works by combining two local anesthetic agents (lidocaine and tetracaine) with a breakthrough CHADD(R) (controlled heat-assisted drug delivery) system and was licensed from ZARS Pharma, Inc. The novel CHADD system combined with the choice of the two local anesthetic ... To continue reading the...
[read full story]